Henry Lau is a notable inventor based in Martinsville, NJ (US). He has made significant contributions to the field of cancer treatment through his innovative research and patented compositions. With a total of 2 patents, Lau's work focuses on the development of effective therapeutic options for patients.

Latest Patents

Henry Lau's latest patents include compositions containing decitabine, 5-azacytidine, and tetrahydrouridine. These compositions are designed for the treatment of cancer and are administered in pill form to human subjects. The administration is guided by the measurement of predictive biomarkers, allowing for a sequential or alternating approach to treatment. This innovative method aims to enhance the efficacy of cancer therapies.

Career Highlights

Lau's career is marked by his dedication to advancing cancer treatment through research and innovation. His work at Epidestiny, Inc. has positioned him as a key player in the development of new therapeutic strategies. His contributions have the potential to significantly impact patient outcomes in oncology.

Collaborations

Henry Lau collaborates with esteemed colleagues such as Yogen Saunthararajah and Joseph Desimone. These partnerships enhance the research efforts at Epidestiny, Inc. and contribute to the advancement of cancer treatment methodologies.

Conclusion

Henry Lau's innovative work and patented compositions represent a significant step forward in cancer treatment. His dedication to research and collaboration with other experts in the field underscores the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.